Achilles Therapeutics (ACHL) Competitors $1.15 +0.01 (+0.88%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ACHL vs. ARTV, PRQR, NLTX, PROC, ZNTL, HURA, IKT, CYBN, CGEN, and CRDFShould you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Artiva Biotherapeutics (ARTV), ProQR Therapeutics (PRQR), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Zentalis Pharmaceuticals (ZNTL), TuHURA Biosciences (HURA), Inhibikase Therapeutics (IKT), Cybin (CYBN), Compugen (CGEN), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry. Achilles Therapeutics vs. Artiva Biotherapeutics ProQR Therapeutics Neoleukin Therapeutics Procaps Group Zentalis Pharmaceuticals TuHURA Biosciences Inhibikase Therapeutics Cybin Compugen Cardiff Oncology Artiva Biotherapeutics (NASDAQ:ARTV) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking. Does the media refer more to ARTV or ACHL? In the previous week, Achilles Therapeutics had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 1 mentions for Achilles Therapeutics and 0 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.00 beat Achilles Therapeutics' score of -0.01 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Artiva Biotherapeutics Neutral Achilles Therapeutics Neutral Which has stronger valuation and earnings, ARTV or ACHL? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtiva BiotherapeuticsN/AN/AN/AN/AN/AAchilles TherapeuticsN/AN/A-$69.67M-$1.65-0.70 Is ARTV or ACHL more profitable? Artiva Biotherapeutics' return on equity of 0.00% beat Achilles Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Artiva BiotherapeuticsN/A N/A N/A Achilles Therapeutics N/A -54.45%-47.68% Do analysts rate ARTV or ACHL? Artiva Biotherapeutics currently has a consensus price target of $21.00, indicating a potential upside of 197.03%. Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 247.83%. Given Achilles Therapeutics' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Artiva Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Achilles Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals believe in ARTV or ACHL? 56.4% of Achilles Therapeutics shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor ARTV or ACHL? Achilles Therapeutics received 8 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote. CompanyUnderperformOutperformArtiva BiotherapeuticsOutperform Votes9100.00% Underperform VotesNo VotesAchilles TherapeuticsOutperform Votes1754.84% Underperform Votes1445.16% SummaryArtiva Biotherapeutics beats Achilles Therapeutics on 6 of the 11 factors compared between the two stocks. Get Achilles Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHL vs. The Competition Export to ExcelMetricAchilles TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.27M$3.01B$5.40B$9.13BDividend YieldN/A1.89%5.37%4.00%P/E Ratio-0.7046.0188.8317.53Price / SalesN/A295.351,284.8780.52Price / CashN/A189.5236.6032.90Price / Book0.334.004.964.69Net Income-$69.67M-$40.99M$117.89M$224.57M7 Day Performance-1.71%3.23%2.74%3.33%1 Month Performance17.35%0.60%3.63%5.33%1 Year Performance39.78%-0.09%27.26%22.97% Achilles Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHLAchilles Therapeutics2.711 of 5 stars$1.15+0.9%$4.00+247.8%+38.6%$47.27MN/A-0.70250Positive NewsARTVArtiva BiotherapeuticsN/A$7.66-18.1%$21.00+174.2%N/A$186.05M$2.60M0.0081Gap DownPRQRProQR Therapeutics2.7894 of 5 stars$2.27-6.2%$8.83+289.1%+13.9%$185.41M$17.88M-7.09180NLTXNeoleukin TherapeuticsN/A$19.58-8.9%N/A-44.8%$184.01MN/A-6.3090Gap DownHigh Trading VolumePROCProcaps GroupN/A$1.63+1.9%N/A-60.6%$183.90M$414.10M3.135,500Positive NewsGap UpZNTLZentalis Pharmaceuticals2.9642 of 5 stars$2.56-6.9%$10.00+290.6%-82.6%$182.44M$40.56M-1.03160Positive NewsHURATuHURA BiosciencesN/A$4.31-11.1%$13.00+201.6%N/A$182.25MN/A0.00N/APositive NewsIKTInhibikase Therapeutics1.647 of 5 stars$2.66-9.8%$6.50+144.4%+58.2%$178.73M$260,000.00-1.006News CoverageCYBNCybin2.8012 of 5 stars$8.90+0.1%$138.00+1,450.6%N/A$177.93MN/A-1.3450News CoveragePositive NewsCGENCompugen2.2916 of 5 stars$1.99+21.3%$4.00+101.0%+16.0%$177.58M$59.85M99.5070Gap UpHigh Trading VolumeCRDFCardiff Oncology2.1585 of 5 stars$3.47-3.9%$10.33+197.8%+128.5%$177.44M$688,000.00-3.6920Positive News Related Companies and Tools Related Companies ARTV Alternatives PRQR Alternatives NLTX Alternatives PROC Alternatives ZNTL Alternatives HURA Alternatives IKT Alternatives CYBN Alternatives CGEN Alternatives CRDF Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACHL) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achilles Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achilles Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACHL Stock Alerts